Coagulation factor viia Intravenous and Enbrel

• Generic Name: coagulation factor viia
• Dosage Forms: n.a.
• Other Brand Names:

  NovoSeven RT with MixPro, Novoseven, NovoSeven RT

Factor VIIa is used to treat and prevent bleeding episodes in patients with Hemophilia A or B who have formed antibodies against other clotting proteins (eg, Factor VIII or Factor IX) that help bleeding to stop. It is also used to treat or prevent bleeding in patients with acquired hemophilia, congenital Factor VII deficiency, or Glanzmann's thrombasthenia (a bleeding disorder that is caused by a blood abnormality) that has been treated with platelet transfusions but did not work well.

Factor VIIa is a man-made protein produced to replicate the naturally occurring activated factor VII (factor VIIa) in the body. It is used to stop bleeding of injuries for patients with hemophilia by helping the blood to clot.

Factor VIIa is to be given only by or under the direct supervision of your doctor.

• Generic Name: etanercept
• Dosage Forms: subcutaneous injection
• Other Brand Names: Enbrel, Enbrel Prefilled Syringe, Enbrel SureClick, Erelzi Prefilled Syringe, Erelzi Sensoready Pen, Enbrel Mini Prefilled Cartridge

Enbrel (etanercept) is a tumor necrosis factor (TNF) blocker. It works by decreasing TNF, a protein produced by the immune system to helps the body fight infections. In people with autoimmune disorders, the immune system produces too much TNF and mistakenly attacks healthy cells.

Enbrel is used to treat rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, and to prevent joint damage caused by these conditions.

Enbrel is also used to treat polyarticular juvenile idiopathic arthritis in children who are at least 2 years old.

Enbrel is also used to treat plaque psoriasis in adults and children who are at least 4 years old.